Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 240Gastrointestinal 21Gynecologic 10Tumor-Agnostic 9CNS 9Thoracic 8Genitourinary 8Other solid neoplasm 5Lymphoid 5Plasma cell 4Other hematologic neoplasm 4Head & Neck 3Sarcoma 2Endocrine 2Dermatologic 2NET 1Myeloid 1Classical hematology 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Hemangiosarcoma 1

Interventions

Radiotherapy 221Cyclophosphamide 211Doxorubicin 210Temozolomide 182Ifosfamide 121Filgrastim 111Imatinib Mesylate 104Etoposide 101Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 81Irinotecan 79pembrolizumab 75Radiation 70Carboplatin 65Methotrexate 62pazopanib 61Nivolumab 58Cisplatin 58fludarabine phosphate 57Surgical Procedures, Operative 57Peripheral Blood Stem Cell Transplantation 57Specimen Handling 56Trabectedin 52Docetaxel 50Biopsy 50Busulfan 49Melphalan 46Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
pertuzumab × Sarcoma × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡